Application Due Date: July 3, 2023
This Notice of Funding Opportunity (NOFO) will support analyses of existing RADx-UP data by proposing novel questions related to SARS-CoV-2 testing and health disparities. These projects will explore important questions focused on COVID-19 testing access and uptake, factors affecting testing and related COVID-19 outcomes, and meta-analyses of specific COVID-19 response and intervention approaches within and across populations.
The funding for this program is provided from the American Rescue Plan Act of 2021, Public Law 117-2.
Topics: Clinical Presentation of Infection, ARDS, Cellular / Molecular Response, Inflammation, Long-term Impact of Infection, Pneumonia, Sensory, Co-Morbidities, Asthma, Cancer, Cardiovascular Disease, Cirrhosis, COPD, COVID-19, Diabetes, Gastroesophageal Reflux Disease (GERD), Hidradentis Supporativa, Immune Disorders, HIV, Immunosuppression, Inflammation, Rheumatoid Disorders, Neurological Disorders, Substance Abuse, Community Engagement, Computational Analysis, Computational or Data Science Methods Development, Diagnostics, Diagnostics Development, Diagnostic Efficacy, Diagnostic Reliability, Diagnostic Scalability, Economic Impact, Education and Training, ELSI (Ethical, Legal, and Social Implications), Environmental Health, Epidemiology, Clinical History, Clinical Outcome, Contact Tracing, Incidence, Risk Factors, Surveillance, Transmission, Health Disparities, Mental Health, Psychology, Mobile Health, App, Telemedicine, Wearables, Occupational Health, Oral Science / Dentistry, Prevention, PPE, Social Distancing, Prognostics, Research Site, Community-based, Vaccine Development, Vaccine Efficacy, Vaccine Reliability, Vaccine Scalability, Vaccines, Vaccine Hesitancy, Research Tool Development, Social Determinants of Health, Target Population, Children, Deaf Persons, Elderly, Homeless Persons, Pregnant Women, Prisoners, Service Workers, Teens, Treatments, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Drugs, Antibody-based Treatment, Convalescent Serum, Drug Targets